On April 30, 2026, the US Food and Drug Administration approved Auvelity (dextromethorphan combined with bupropion, also known as AXS-05) for agitation associated with Alzheimer's disease, the first non-antipsychotic on-label option for an indication that had relied on off-label antipsychotic prescribing for 30 years (Drugs@FDA Auvelity application 211810; DailyMed Auvelity label). Auvelity joins brexpiprazole (Rexulti, approved May 2023) as one of only two FDA-approved drugs for Alzheimer's-associated agitation, and is the first that does not carry an antipsychotic-mortality boxed warning for elderly patients with dementia-related psychosis.
Auvelity's label, unlike risperidone, olanzapine, quetiapine, and other off-label drugs, does not carry the boxed warning for increased mortality in elderly dementia-related-psychosis patients. What the approval changes for Black dementia patients specifically, given that older Black Americans are about twice as likely as older White Americans to have Alzheimer's or other dementias (Alzheimer's Association 2026 Facts and Figures), depends on three different research findings held in the same hand.
What the literature actually shows about Black-patient antipsychotic prescribing in dementia
A 2020 analysis of UK primary-care records covering 53,718 people with dementia found that Black patients on an antipsychotic were prescribed it for 27 days per year longer than white patients (mean 200.7 days vs roughly 173.7 days for white peers), even though Black patients were no more likely to be initiated on one in the first place (Jones et al., Clinical Epidemiology 2020; PMID 32021472). That finding is a duration disparity, not a rate disparity. It is also a UK finding.
The US data runs the opposite direction. A 2024 study of 2017-2019 Medicare fee-for-service data found that Black persons living with dementia were 11.7 percentage points less likely than white patients to be diagnosed with the behavioral and psychological symptoms of dementia (BPSD) (56.6 percent vs 68.3 percent), and 8.5 percentage points less likely to receive a central-nervous-system-active drug conditional on diagnosis (70.8 percent vs 79.3 percent) (Thunell et al., Journal of Alzheimer's Disease 2024; PMID 38669535). A 2025 Health Affairs Scholar analysis of community-dwelling Medicare older adults with dementia 2010 through 2018 documents that overall antipsychotic prescribing rose from 9.4 percent in 2010-2012 to 15.8 percent in 2013-2015 and remained at 16.0 percent in 2016-2018 across the Choosing Wisely watershed; the published full-text race-stratified figures show racial and ethnic minority patients were less likely than white patients to receive antipsychotics across all three time periods (Yang et al., Health Affairs Scholar 2025; PMID 40040648). And a 2025 JAMA Network Open analysis of more than 21 million Medicare beneficiaries from 2016 through 2019 found that white beneficiaries had consistently higher rates of potentially inappropriate medication use than Asian or Pacific Islander, Black, and Hispanic beneficiaries, with Black-versus-white high-risk medication use lower by 3.4 percentage points (Raver et al., JAMA Network Open 2025; PMID 40227682).
Three independent US Medicare-based studies covering 2010-2018, 2016-2019, and 2017-2019 all show Black PLWD underdiagnosed for BPSD or undertreated with CNS-active or potentially inappropriate medications, compared with white peers. The honest framing of the disparity in Black-patient dementia care is differently inappropriate, not overprescribed. The "Black patients are overprescribed antipsychotics" version of the story is unsupported by US Medicare data and mis-represents the Jones et al. UK finding.
What Auvelity is and what its label actually says
Auvelity combines dextromethorphan hydrobromide (an NMDA-receptor antagonist and sigma-1 receptor agonist) with bupropion hydrochloride (added to inhibit the CYP2D6 enzyme that would otherwise rapidly metabolize the dextromethorphan). The mechanism is distinct from the dopamine D2 receptor antagonism that defines antipsychotics.
The Auvelity label carries the standard bupropion antidepressant boxed warning for suicidal thoughts and behaviors in pediatric and young-adult patients. It does not carry the antipsychotic-mortality boxed warning that risperidone, olanzapine, quetiapine, and other off-label drugs carry for elderly dementia-related-psychosis patients. The Warnings and Precautions section flags clinically significant hyponatremia in geriatric patients as a notable adverse-event signal (DailyMed Auvelity label). The FDA antipsychotic-mortality boxed warning, in place since 2005, is the standing safety signal that prompted the Choosing Wisely "avoid antipsychotics for dementia agitation" recommendation in the first place.
The Black-relevance constraint on the Auvelity registration package
The original ADVANCE Phase 2/3 trial enrolled 42 Black participants out of 366 total, or 11.5 percent of the trial (NCT03226522). That is below the 13 percent Black share of the US adult population and well below the higher Black share of the US dementia population that follows from the roughly 2x dementia prevalence in older Black Americans. The two larger registration-supportive trials, ADVANCE-2 and ACCORD-2, have race and ethnicity baseline characteristics not yet posted in the ClinicalTrials.gov results section as of May 7, 2026 (NCT05557409; NCT04947553). Until the registration-package race data post or appear in peer-reviewed publication, the Black-relevance of the AXS-05 efficacy and safety data should be read as partially evidenced (anchored in the ADVANCE 11.5 percent figure) rather than confirmed across the registration package.
Why the access question is the real Black-dementia question
The Thunell, Yang, and Raver findings together describe an upstream constraint on whether Auvelity matters for Black dementia patients in practice. If Black PLWD are less likely to be diagnosed with BPSD (Thunell), to receive antipsychotics across Choosing Wisely periods (Yang full text), or to receive potentially inappropriate medications (Raver), then the structural pattern is that Black families reach a clinical decision point on agitation less often, and when they do, the patient is treated less often. The Auvelity approval changes the on-label menu; it does not change whether a Black patient gets to a clinician who recognizes BPSD and writes a prescription.
Coverage is the second access lever. Auvelity is a brand-name newer drug; Medicare Part D formulary placement and copay tier will determine whether the price-friction layer that historically depresses Black-Medicare-beneficiary uptake of brand-name CNS drugs also depresses Auvelity uptake. Axsome had not announced 2026 wholesale acquisition cost or Part D posture as of this filing.
Three named voices on the evidence layer
Annie W. Yang, MD, is in the Division of General Internal Medicine and Health Services Research at the David Geffen School of Medicine at UCLA, and led the Health Affairs Scholar 2025 trends paper on community-dwelling antipsychotic prescribing in dementia. Nina T. Harawa, PhD, MPH, is at the same UCLA division and was senior co-author on the Yang paper, with a longstanding research focus on health-equity in older-adult care. Eli Raver, PharmD, is in the Division of Health Services Management and Policy at Ohio State University College of Public Health, and led the JAMA Network Open 2025 analysis of racial and ethnic differences in potentially inappropriate medication use among Medicare beneficiaries.
What the evidence does not yet tell us
Three things the published literature does not currently pin down. First, the Black-enrollment percentages in ADVANCE-2 and ACCORD-2 are not yet posted on ClinicalTrials.gov; the Black-relevance of the registration-package efficacy and safety data is anchored only in the original 11.5 percent ADVANCE figure until those numbers post or appear in peer review. Second, the Auvelity wholesale acquisition cost and Medicare Part D formulary tier are not yet public; expect both on Axsome's Q2 2026 earnings call. Third, the structural disparities documented in the US Medicare evidence base may either suppress or accelerate Black-patient Auvelity uptake; the answer requires 12 to 24 months of post-launch real-world evidence stratified by race and ethnicity.
What you can do this week
Three concrete actions for a Black caregiver of a person living with dementia.
First, ask the prescribing clinician whether Auvelity is a reasonable first-line on-label option for agitation symptoms specifically, rather than an off-label antipsychotic. The label's lack of an antipsychotic-mortality boxed warning is the clinical-decision argument for raising the question; the prescription decision sits with the clinician based on the patient's symptom profile, comorbidities, and medication history.
Second, ask about BPSD diagnosis and assessment if the dementia diagnosis exists in the chart but the agitation, depression, or psychosis symptoms have not been formally documented as BPSD. The 11.7 percentage-point lower BPSD diagnosis rate among Black PLWD (Thunell et al., 2024) makes the assessment-and-documentation step load-bearing; a formal BPSD diagnosis is the gate to any FDA-approved on-label treatment, including Auvelity.
Third, verify Medicare Part D or Medicare Advantage coverage and prior-authorization requirements before the prescription is written. Brand-name newer CNS drugs typically launch at Tier 3 or higher Part D placement; prior-authorization friction is the documented mechanism by which Black Medicare beneficiaries discontinue brand-name prescriptions at higher rates than white peers. The Medicare Plan Finder (medicare.gov/plan-compare) is the primary-source tool for current-year plan detail.
For finding a geriatric specialist or memory-care clinician who can make the BPSD assessment, the Black Health provider directory lists psychiatrists, neurologists, and primary-care clinicians with verified licenses; our piece on why finding a Black doctor is harder than it should be covers the workforce numbers behind the search difficulty.
Update plan
We will update this piece when ADVANCE-2 and ACCORD-2 race and ethnicity baseline data post on ClinicalTrials.gov, when Auvelity wholesale acquisition cost and Medicare Part D formulary tier are announced, when Phase 4 or post-marketing race-stratified uptake data appears, or when the FDA April 30, 2026 press release URL stabilizes.
Citations
Jones ME, Petersen I, Walters K, et al. Differences in Psychotropic Drug Prescribing Between Ethnic Groups of People with Dementia in the United Kingdom. Clinical Epidemiology. 2020;12:61-71. PMID 32021472.
Thunell JA, Joyce GF, Ferido PM, et al. Diagnoses and Treatment of Behavioral and Psychological Symptoms of Dementia Among Racially and Ethnically Diverse Persons Living with Dementia. Journal of Alzheimer's Disease. 2024. PMID 38669535.
Yang AW, Leng M, Arbanas JC, et al. Trends in antipsychotic prescribing among community-dwelling older adults with dementia, 2010-2018. Health Affairs Scholar. 2025. PMID 40040648.
Raver E, Jung J, Carlin C, et al. Racial and Ethnic Differences in Potentially Inappropriate Medication Use Among Medicare Beneficiaries. JAMA Network Open. 2025. PMID 40227682.
Alzheimer's Association. 2026 Alzheimer's Disease Facts and Figures. alz.org.
